Jonathan Zalevsky Sells 10,300 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Jonathan Zalevsky sold 10,300 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total value of $10,403.00. Following the sale, the insider now owns 316,604 shares in the company, valued at approximately $319,770.04. This represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Price Performance

Shares of NASDAQ:NKTR traded up $0.03 during trading on Tuesday, hitting $0.87. The company's stock had a trading volume of 2,801,493 shares, compared to its average volume of 2,437,055. The firm has a market cap of $160.57 million, a price-to-earnings ratio of -1.04 and a beta of 0.58. The company has a 50-day moving average of $0.91 and a 200-day moving average of $1.11. Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93.

Institutional Trading of Nektar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC boosted its stake in shares of Nektar Therapeutics by 56.3% during the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 9,958 shares during the last quarter. Harvest Investment Services LLC purchased a new position in Nektar Therapeutics during the fourth quarter valued at $27,000. US Asset Management LLC bought a new stake in Nektar Therapeutics during the fourth quarter valued at about $31,000. Valence8 US LP purchased a new stake in Nektar Therapeutics in the third quarter worth about $34,000. Finally, Intech Investment Management LLC bought a new position in shares of Nektar Therapeutics in the third quarter worth about $41,000. 75.88% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

NKTR has been the subject of several research analyst reports. Piper Sandler began coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $6.50 price target on shares of Nektar Therapeutics in a research note on Tuesday. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price objective on the stock. Finally, William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.